CONCLUSION:GCS-unresponsive patients responded well to TPE. Relevant clinical and paraclinical predictive factors for TPE response are presented to supplement the existing literature.Disclosure: Dr. Ehler has nothing to disclose. Dr. Sauer has nothing to disclose. Dr. Koball has nothing to disclose. Dr. Mitzner has nothing to disclose. Dr. Hickstein has nothing to disclose. Dr. Benecke has received research support from Merz Pharma. Dr. Zettl has received personal compensation for activities with Bayer Healthcare, Biogen Idec, Genzyme, Merck-Serono, Novartis, and Teva. (Source: Neurology)